A risk score model based on TGF-β pathway-related genes predicts survival, tumor microenvironment and immunotherapy for liver hepatocellular carcinoma

Liao, Jingsheng; Liu, Qi; Chen, Jingtang; Lu, Zhi‐Bin; Mo, Huiting; Ju, Jia

doi:10.1186/s12953-022-00192-4

Cited by 4 publications

(4 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TGF-b signal activation stimulates EMT, facilitating metastasis and chemical resistance (11,18). In recent years, many studies shown that TGF-b signal gene signature have a favorable capacities for predicting prognosis and responses to treatment of cancer (15,16,19). Several studies have reported that TGF-b pathway transduction disorder is very common in ccRCC and that inhibition of TGF-b pathway is considered to be a promising forms of treatment for ccRCC (20,21).…”

Section: Discussionmentioning

confidence: 99%

“…In recent years, with the increasing development of bioinformatics, the use of TGF-b signaling pathway-related genes signature as biomarker and prognostic models in malignant tumor has attracted wide attention. Liao et al established 8-gene signature as a risk model based on TGF-b signaling pathway-related genes to predict prognosis and immunotherapy of liver hepatocellular carcinoma (15). In addition, Yu et al developed a 5-gene prognostic model based on TGF-b signaling-related genes to evaluate the clinical outcomes, immunotherapy response and targeted therapy of lung adenocarcinoma (16).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development of a TGF-β signaling-related genes signature to predict clinical prognosis and immunotherapy responses in clear cell renal cell carcinoma

Xie²,

Gong³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundTransforming growth factor (TGF)-β signaling is strongly related to the development and progression of tumor. We aimed to construct a prognostic gene signature based on TGF-β signaling-related genes for predicting clinical prognosis and immunotherapy responses of patients with clear cell renal cell carcinoma (ccRCC).MethodsThe gene expression profiles and corresponding clinical information of ccRCC were collected from the TCGA and the ArrayExpress (E-MTAB-1980) databases. LASSO, univariate and multivariate Cox regression analyses were conducted to construct a prognostic signature in the TCGA cohort. The E-MTAB-1980 cohort were used for validation. Kaplan-Meier (K-M) survival and time-dependent receiver operating characteristic (ROC) were conducted to assess effectiveness and reliability of the signature. The differences in gene enrichments, immune cell infiltration, and expression of immune checkpoints in ccRCC patients showing different risks were investigated.ResultsWe constructed a seven gene (PML, CDKN2B, COL1A2, CHRDL1, HPGD, CGN and TGFBR3) signature, which divided the ccRCC patients into high risk group and low risk group. The K-M analysis indicated that patients in the high risk group had a significantly shorter overall survival (OS) time than that in the low risk group in the TCGA (p < 0.001) and E-MTAB-1980 (p = 0.012). The AUC of the signature reached 0.77 at 1 year, 0.7 at 3 years, and 0.71 at 5 years in the TCGA, respectively, and reached 0.69 at 1 year, 0.72 at 3 years, and 0.75 at 5 years in the E-MTAB-1980, respectively. Further analyses confirmed the risk score as an independent prognostic factor for ccRCC (p < 0.001). The results of ssGSEA that immune cell infiltration degree and the scores of immune-related functions were significantly increased in the high risk group. The CIBERSORT analysis indicated that the abundance of immune cell were significantly different between two risk groups. Furthermore, The risk score was positively related to the expression of PD-1, CTLA4 and LAG3.These results indicated that patients in the high risk group benefit more from immunotherapy.ConclusionWe constructed a novel TGF-β signaling-related genes signature that could serve as an promising independent factor for predicting clinical prognosis and immunotherapy responses in ccRCC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Development of a TGF-β signaling-related genes signature to predict clinical prognosis and immunotherapy responses in clear cell renal cell carcinoma

Xie²,

Gong³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…An increasing number of risk models related to pyroptosis, autophagy, ferroptosis, and glucose metabolism have been constructed with the potential value to predict prognosis and guide individualized treatment for GBM (41)(42)(43). Several studies investigating the prognostic prediction in tumors of TGF-β signature have been published, such as hepatocellular carcinoma, lung adenocarcinoma, and bladder cancer (44)(45)(46). In this study, the optimal candidate genes were firstly screened from TGF-β related genes with several programs, including univariate and multivariate Cox analyses.…”

Section: Discussionmentioning

confidence: 99%

TGF-β based risk model to predict the prognosis and immune features in glioblastoma

Liu

Wei

et al. 2023

Front. Neurol.

View full text Add to dashboard Cite

BackgroundTransforming growth factor-β (TGF-β) is a multifunctional cytokine with an important role in tissue development and tumorigenesis. TGF-β can inhibit the function of many immune cells, prevent T cells from penetrating into the tumor center, so that the tumor cells escape from immune surveillance and lead to low sensitivity to immunotherapy. However, its potential roles in predicting clinical prognosis and tumor microenvironment (TME) immune features need to be deeply investigated in glioblastoma (GBM).MethodsThe TCGA-GBM dataset was obtained from the Cancer Genome Atlas, and the validation dataset was downloaded from Gene Expression Omnibus. Firstly, differentially expressed TGF-β genes (DEGs) were screened between GBM and normal samples. Then, univariate and multivariate Cox analyses were used to identify prognostic genes and develop the TGF-β risk model. Subsequently, the roles of TGF-β risk score in predicting clinical prognosis and immune characteristics were investigated.ResultsThe TGF-β risk score signature with an independent prognostic value was successfully developed. The TGF-β risk score was positively correlated with the infiltration levels of tumor-infiltrating immune cells, and the activities of anticancer immunity steps. In addition, the TGF-β risk score was positively related to the expression of immune checkpoints. Besides, the high score indicated higher sensitivity to immune checkpoint inhibitors.ConclusionsWe first developed and validated a TGF-β risk signature that could predict the clinical prognosis and TME immune features for GBM. In addition, the TGF-β signature could guide a more personalized therapeutic approach for GBM.

show abstract

“…We further analyzed the expression of TGF-β between people with PAD and healthy people groups. Liao reported 54 genes associated with TGF-β from MSigDB (v7.4) [ 14 ]. To determine the expressions of TGF-β-related genes between the PAD and control groups, a gene box map was created using R software (4.1.2).…”

Section: Identification and Analysis Of Special Pathwaysmentioning

confidence: 99%

The Role of TGF-β Signaling in Saphenous Vein Graft Failure after Peripheral Arterial Disease Bypass Surgery

Zhang

et al. 2023

IJMS

View full text Add to dashboard Cite

Saphenous vein bypass grafting is an effective technique used to treat peripheral arterial disease (PAD). However, restenosis is the major clinical challenge for the graft vessel among people with PAD postoperation. We hypothesize that there is a common culprit behind arterial occlusion and graft restenosis. To investigate this hypothesis, we found TGF-β, a gene specifically upregulated in PAD arteries, by bioinformatics analysis. TGF-β has a wide range of biological activities and plays an important role in vascular remodeling. We discuss the molecular pathway of TGF-β and elucidate its mechanism in vascular remodeling and intimal hyperplasia, including EMT, extracellular matrix deposition, and fibrosis, which are the important pathways contributing to stenosis. Additionally, we present a case report of a patient with graft restenosis linked to the TGF-β pathway. Finally, we discuss the potential applications of targeting the TGF-β pathway in the clinic to improve the long-term patency of vein grafts.

show abstract

A risk score model based on TGF-β pathway-related genes predicts survival, tumor microenvironment and immunotherapy for liver hepatocellular carcinoma

Cited by 4 publications

References 47 publications

Development of a TGF-β signaling-related genes signature to predict clinical prognosis and immunotherapy responses in clear cell renal cell carcinoma

Development of a TGF-β signaling-related genes signature to predict clinical prognosis and immunotherapy responses in clear cell renal cell carcinoma

TGF-β based risk model to predict the prognosis and immune features in glioblastoma

The Role of TGF-β Signaling in Saphenous Vein Graft Failure after Peripheral Arterial Disease Bypass Surgery

Contact Info

Product

Resources

About